Bio Search Signs Share-Exchange Deal for Brain-AI Firm InnerEye
What happened
On November 9, 2026, Japan's Bio Search announced it had signed a share-exchange agreement to acquire 100% of InnerEye, an Israeli company that develops AI for real-time brain signal analysis. The deal would make InnerEye a wholly owned subsidiary of Bio Search, with plans to integrate InnerEye's expert-decision technology into Bio Search's healthcare AI business. The acquisition is subject to regulatory approval from Israeli authorities and is expected to close between December 2026 and early January 2027. Completion of the transaction has not yet occurred.
Key details
- InnerEye was founded in 2014 by Amir Geva and Leon Deouell, both professors in Israel.
- InnerEye’s technology includes Minded A.I., which digitizes expert judgment for AI training, and SensePlus, which monitors cognitive and emotional states such as fatigue and attention.
- Bio Search currently works with EEG, ECG, heart-rate, and EMG signals in healthcare AI.
- The integration plan involves pooling EEG and other biological data from both companies to train AI models.
- Bio Search has set a target to list on Nasdaq in 2028 as part of its expansion strategy.
Why it matters
Healthcare providers, device makers, and industrial users in Japan and Asia could gain access to new AI tools that combine real-time brain signal analysis with existing biological sensing technologies. The deal creates a pathway for Bio Search to expand its product capabilities and reach, while InnerEye’s technology may be commercialized on a larger scale. Regulatory approval is now the main hurdle before the companies can begin integrating their operations and data.